AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00631514
Drug: ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: acetaminophen 1000 mg t.i.d. per os ibuprofen 400-600 mg t.i.d. per os piroxicam 10-20 mg o.d. per os
Trial: NCT00631514
Drug: piroxicam
RxNorm normalized name: Piroxicam
DrugBank: Piroxicam (DB00554)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: acetaminophen 1000 mg t.i.d. per os ibuprofen 400-600 mg t.i.d. per os piroxicam 10-20 mg o.d. per os
Trial: NCT00135031
Drug: Bifidobacterium infantis 35624
RxNorm normalized name: bifidobacterium infantis 35624
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02151058
Drug: Colgate® Regular Cavity Protection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brushing twice daily with an ADA - Accepted fluoride - containing dentifrice (Colgate Cavity Protection)
Trial: NCT01010880
Drug: BKT140
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BKT-140 drug substance is a highly selective CXCR4 antagonist. BKT140 will be injected S.C once at dose of 0.03, 0.1, 0.3, 0.9 mg/kg
Trial: NCT01631214
Drug: Placebo to Alendronate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablet taken once a week during the double-blind treatment phase.
Trial: NCT03117751
Drug: Erwinase®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To be used in case of hypersensitivity or intolerance to Pegaspargase or if Pegaspargase is not available. Given IV or intramuscularly (IM).
Trial: NCT03117751
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV.
Trial: NCT03117751
Drug: Mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO.
Trial: NCT03117751
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV.
Trial: NCT03117751
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV.
Trial: NCT04144257
Drug: [C-11]Methylreboxetine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PET radiopharmaceutical. Subjects will undergo \[C-11\]MRB-PET (norepinephrine transporter binding).
Trial: NCT00745004
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule matching over-encapsulated experimental drug. 1 capsule OD, dose titrated up to a maximum of 2 capsules tds or down to a minimum of 1 capsule alternate days. For 5 weeks.
Trial: NCT04112316
Drug: Liothyronine
RxNorm normalized name: Liothyronine
DrugBank: Liothyronine (DB00279)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liothyronine (L-triiodothyronine or LT3) in the 5 mcg tablet dose formulation. Minimum LT3 dose was 2.5 mcg three times daily and the maximum LT3 dose was 12.5 mcg three times daily.
Trial: NCT02534181
Drug: Caloric Management Protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strategy based on reduction of nutritional intake and electrolyte replacement.
Trial: NCT04270526
Drug: Standard protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradetrussor treatment with 50 mL 1% lidocaine + 50ml of 0.9% normal saline
Trial: NCT00055393
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 21 subjects received Placebo.
Trial: NCT00003403
Drug: GPX-100
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02473250
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bipolar depressed patients will be treated with fluoxetine in combination with a mood stabilizer (valproate).
Trial: NCT03954366
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single dose of 20mg oral rosuvastatin on Day 1 and Day 19 only.
Trial: NCT00904943
Drug: Topamax® Capsules, 25 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 x 25 mg Capsules
Trial: NCT06781073
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo in combined with chemotherapy period, 400mg, day1, administered intravenously before chemotherapy ,weekly, for 18 weeks; Maintenance period, 400mg, every two weeks until disease progression or intolerable toxicity , maximum duration is 60 weeks .
Trial: NCT00688987
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Subjects will receive in random order daily (split) dosing of hydrocortisone: a low dose of 15 mg (10 in AM, 5 in PM); a medium dose of 25 mg (15 in AM, 10 in PM) and high dose of 40 mg (30 in AM, 10 in PM) for 4 months.
Trial: NCT04342858
Drug: Fluoride Varnish with tricalcium phosphate
RxNorm normalized name: tricalcium phosphate
DrugBank: Calcium citrate (DB11093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clinpro white varnishTM, 3M ESPE, St Paul, MN, USA
Trial: NCT01539616
Drug: ZYH7
RxNorm normalized name: I do not have enough information to determine the full generic name for the drug abbreviation 'ZYH7'. Drug abbreviations can vary and may not have a standardized full generic name. Without more context about the specific drug or clinical trial data, I cannot provide the full generic name. I apologize that I cannot give you a more definitive answer.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZYH7 4mg given once orally in the morning before breakfast, for 8 weeks.
Trial: NCT01539616
Drug: ZYH7
RxNorm normalized name: I do not have enough information to determine the full generic name for the drug abbreviation 'ZYH7'. Drug abbreviations can vary and may not have a standardized full generic name. Without more context about the specific drug or clinical trial data, I cannot provide the full generic name. I apologize that I cannot give you a more definitive answer.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZYH7 8 mg given once orally in the morning before breakfast, for 8 weeks.
Trial: NCT01539616
Drug: ZYH7
RxNorm normalized name: I do not have enough information to determine the full generic name for the drug abbreviation 'ZYH7'. Drug abbreviations can vary and may not have a standardized full generic name. Without more context about the specific drug or clinical trial data, I cannot provide the full generic name. I apologize that I cannot give you a more definitive answer.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZYH7 16 mg given once orally in the morning before breakfast, for 8 weeks.
Trial: NCT03039699
Drug: Ergoferon
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03039699
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00422942
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10-25mg po weekly
Trial: NCT03715127
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose of placebo (100% mannitol)
Trial: NCT00149227
Drug: Non-ARB
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 'Non-ARB' was defined conventional anti-hypertensive treatment except for ACEIs and ARBs
Trial: NCT00544674
Drug: PR104
RxNorm normalized name: PR104
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered at a dose of 1100 mg/m\^2 by intravenous infusion over 1 hour and repeated every three weeks
Trial: NCT00129220
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo, oral tablets, twice daily (morning and evening), for 3 weeks
Trial: NCT02895074
Drug: Proparacaine hydrochloride
RxNorm normalized name: Proparacaine Hydrochloride
DrugBank: Proparacaine (DB00807)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: topical anesthesia with proparacaine hydrochloride (0.5%) was applied.
Trial: NCT03626454
Drug: Norepinephrine Bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 'Norepinephrine Bitartarte' bolus of 6 µg/mL for 30 seconds immediately after intrathecal injection
Trial: NCT03626454
Drug: Norepinephrine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: an infusion of 6 µg/mL norepinephrine that was started at 6 µg/kg/h immediately after intrathecal injection
Trial: NCT03626454
Drug: Normal Saline Flush, 0.9% Injectable Solution
RxNorm normalized name: Normal Saline Flush, 0.9% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml normal saline in syringe for bolus for 30 seconds immediately after intrathecal injection
Trial: NCT03626454
Drug: Normal Saline 0.9% Infusion Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 ml syringe with normal saline infuse at a rate 1ml/kg/h immediately after intrathecal injection
Trial: NCT03117010
Drug: Steroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose dexamethasone 20 mg PO or IV
Trial: NCT00749866
Drug: Gentamicin
RxNorm normalized name: Gentamicin
DrugBank: Gentamicin (DB00798)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nebulised 80mg twice daily
Trial: NCT02814916
Drug: Clindamycin
RxNorm normalized name: Clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clindamycin was administered orally every 8 hours.
Trial: NCT03804840
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00834977
Drug: Lotrel® 10 mg-20 mg capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 x 10-20 mg
Trial: NCT01112826
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: capecitabine 650 mg/m2 twice every day for 1 year.
Trial: NCT00312156
Drug: insulin NPH
RxNorm normalized name: insulin NPH human isophane
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00876902
Drug: Viaspan® and saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo of a volume equivalent to active study drug will be prepared for administration to the control group to help maintain the blind. Those patients that experience an intraoperative blood loss of \>10 units, will receive an additional 1 mg/kg IV infusion of placebo equivalent at the end of the transplant surgery.
Trial: NCT01494753
Drug: T2345
RxNorm normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One drop at 8.00pm.
Trial: NCT01494753
Drug: Prostaglandin
RxNorm normalized name: Prostaglandin
DrugBank: Prostaglandin G2 (DB03866)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One drop at 8.00pm.
Trial: NCT04492514
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo infusion
Trial: NCT02155166
Drug: ibuprofen 400 mg
RxNorm normalized name: ibuprofen 400 MG
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 hour prior to the LNG-IUS insertion
Trial: NCT03927703
Drug: SB206 12%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topically once daily
Trial: NCT00307658
Drug: Intravenous immunoglobulins (human immunoglobulins G)
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00303719
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide will be given in a two hour infusion, total dose 50 mg/kg on day -6.
Trial: NCT02600715
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo to B\&O suppository
Trial: NCT00656136
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receive placebo once daily
Trial: NCT00656136
Drug: BIBW 2992
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receive afatinib tablets once daily, and can reduce dose for adverse event management. Afatinib is given once daily, continuously until disease progression or unacceptable toxicity.
Trial: NCT01782027
Drug: 3H-cholesterol bound to albumin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: up to 100 uCi of \[3H\]-cholesterol (containing approximately 0.2 mg of cholesterol) mixed with a solution containing human serum albumin will be administered as an intravenous bolus injection
Trial: NCT00006359
Drug: LHRH agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lupron: 22.5mg IM injection q 12 wks x 2 OR Zoladex: 10.8 mg subQ injection q 12 wks x 2
Trial: NCT00006359
Drug: antiandrogen
RxNorm normalized name: Antiandrogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: flutamide 250 mg PO tid for 4 wks OR casodex 50 mg PO daily for 4 wks
Trial: NCT00887822
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matched to bevacizumab on Day 1 of every 3-week cycle
Trial: NCT00887822
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000 mg/m\^2 orally twice daily on Days 1-14 of every 3-week cycle
Trial: NCT02063802
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total dose 6 tablets per day. The patient takes 2 tablets with breakfast, two tablets with lunch and two tablets with dinner by mouth for four months
Trial: NCT01540721
Drug: Marketed paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: marketed formulation
Trial: NCT01540721
Drug: Experimental paracetamol formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental formulation
Trial: NCT00719706
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01110603
Drug: MK-4827
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules, orally, once daily, on Days 1 and 3 of each 21- or 28-day Cycle, at the assigned dose level, starting at 40 mg per dose.
Trial: NCT01110603
Drug: liposomal doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion, 30 mg/m2, once, on Day 3 of each 28-day cycle
Trial: NCT01452685
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-385 placebo-matching tablets, orally, once daily and leuprorelin acetate placebo injection, subcutaneously, once every 4 weeks for up to 12 weeks.
Trial: NCT04276493
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered orally
Trial: NCT02083406
Drug: 800mg OZ439 prototype formulation 1
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02083406
Drug: 800mg OZ439 prototype formulation 2
RxNorm normalized name: Hep B, unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02083406
Drug: 800mg OZ439 prototype formulation 3
RxNorm normalized name: Hep B, unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01917799
Drug: Heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.4 mL/day of the Enoxaparin
Trial: NCT03633461
Drug: OC-02 (simpinicline) nasal spray
RxNorm normalized name: OC 8 Adult Acne
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OC-02 (simpinicline) nasal spray, 11.1 mg/ml
Trial: NCT03633461
Drug: Placebo (vehicle) nasal spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (vehicle) nasal spray
Trial: NCT03682471
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, 10 mM sodium phosphate, 0.9% \[w/v\] sodium chloride in water for subcutaneous injection.
Trial: NCT03585829
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: at a substitutive dosage
Trial: NCT03585829
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: at a substitutive dosage
Trial: NCT02502994
Drug: GEN0101
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02138929
Drug: LDE 225
RxNorm normalized name: LANCET,STERILANCE LDE 2 DEVICE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction Phase Starting Dose: 400 mg by mouth daily in a 28 day cycle.~Expansion Phase Starting Dose: Maximum tolerated dose from Induction Phase.
Trial: NCT02898662
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled Placebo administered at the clinic as once weekly inhalations with the I-neb® device. Start dose is Placebo 4 mg and dose adaptation is applied (downtitration to 1mg or uptitration to 8 mg or remain on 4 mg) based on appearance of flu like adverse events
Trial: NCT00386035
Drug: Delayed ART
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants follow a drug conservation (DC) regimen in which ART is stopped or deferred until CD4 cell count dropped below 250 cells/mm3, initiated until CD4 cell count is at least 350 cells/mm3, and then are followed by episodic ART based on CD4 cell count.
Trial: NCT00386035
Drug: Continuous ART
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 2 participants follow a viral suppression (VS) regimen in which ART was continued to keep viral loads as low as possible, regardless of CD4 cell count.
Trial: NCT03907072
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buffered saline solution
Trial: NCT04586920
Drug: LY3509754
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT04586920
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT01973205
Drug: Acetaminophen 250 mg and Aspirin 250 mg
RxNorm normalized name: Acetaminophen 250 mg and aspirin 250 mg and caffeine 65 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 tablets each containing Acetaminophen 250 mg and Aspirin 250 mg
Trial: NCT01973205
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 placebo tablets matching acetaminophen 250 mg and aspirin 250 mg tablets
Trial: NCT04026113
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo
Trial: NCT00687596
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants randomized to placebo received 2 placebo tablets (identical in appearance to the TAC 101 tablets) administered PO daily with approximately 240 mL (8 oz) of water under fed conditions (no later than 1 hour after a meal) in a regimen identical to that for TAC 101.
Trial: NCT04230759
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receive chemotherapy cycles as followed:~Mitomycin-C 12 mg/m², day 1 (maximum single dose 20 mg) 5-FU: 1000 mg/m² per day, continuous i.v. infusion, on day 1-4 and 29-32
Trial: NCT03970330
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: daily placebo pill, taken orally
Trial: NCT02903771
Drug: Part A: Dose Escalation of Cantrixil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cantrixil will be administered via the intraperitoneal route only. The dose of study drug that each participant will receive will depend on how far the study has progressed when the participant enrols. There are 9 potential doses of Cantrixil, they are 0.06, 0.12, 0.24 (starting dose), 0.6, 1.25, 2.5, 5, 10, or 20 mg/kg. The dose each participant receives will remain the same during the study, unless it needs to be reduced for safety reasons. The dose will not be increased.~Each participant will receive the study drug once a week during the first two cycles; each cycle is 21-days (three weeks); the MTD will be determined during Cycle 1 only. If after two cycles of monotherapy, the patient tolerates Cantrixil adequately, they may continue to receive Cantrixil once a week and will also begin combination chemotherapy for another 6 cycles. Participants will receive no more than 8 cycles of study drug.
Trial: NCT02903771
Drug: Part B: Expansion Cohort of Cantrixil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once the MTD has been established, an expansion cohort will be recruited at the MTD. An additional 12 patients will be recruited in this cohort on top of those recruited in Part A at the MTD. These patients will be subjected to the same intervention described in Part A with 2 cycles of monotherapy followed by up to 6 cycles of combination therapy.
Trial: NCT00733096
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two transforaminal epidural saline injections, two weeks apart
Trial: NCT04073290
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo b.i.d. 72 hours before TIPS placement till 3 months post-TIPS
Trial: NCT04055220
Drug: Treatment by Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment for 13 cycles (12 months) maximum.~During each cycle, patient will take once a day, during 21 days, followed by 7 days without placebo treatment :~* 3 placebo tablets (3 weeks out of 4 weeks) in patients ≥ 16 years old and patients \< 16 years old with BSA ≥ 1.70m²;~* 2 placebo tablets (3 weeks out of 4 weeks) in patients \< 16 years old with 1.30m² ≤ BSA \< 1.70m²;
Trial: NCT01883596
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.4% alcohol, glycerine, normal saline solution, applied topically, every 8 hrs.
Trial: NCT04994860
Drug: BIA 5-1058
RxNorm normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral BIA 5-1058 (Zamicastat) 100 mg tablets
Trial: NCT04506073
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be identical to the investigational product but will not contain mesenchymal stem cells (MSCs).